Loading clinical trials...
Loading clinical trials...
A Phase 2a, Open Label Study to Evaluate the Safety, Tolerability, and Efficacy of CBL-514 Injection for the Treatment of Edematous Fibrosclerotic Panniculopathy (EFP) Cellulite (Stage 1)
Conditions
Interventions
40 mg CBL-514
60 mg CBL-514
+1 more
Locations
2
United States
Investigational Site 1
Encino, California, United States
Investigational Site 2
New York, New York, United States
Start Date
January 9, 2023
Primary Completion Date
May 3, 2023
Completion Date
May 3, 2023
Last Updated
June 22, 2023
NCT05664581
NCT03782545
NCT05959681
NCT05885035
NCT03550157
NCT05748678
Lead Sponsor
Caliway Biopharmaceuticals Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions